Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE)
Status:
Withdrawn
Trial end date:
2024-10-30
Target enrollment:
Participant gender:
Summary
Hepatitis C (HCV) is a chronic infection with significant morbidity and mortality. The
development of directly acting antivirals (DAA) has dramatically improved the cure rate of
HCV treatment. People who experience incarceration are disproportionately infected and often
involved in ongoing transmission of disease. However, despite availability of effective
treatment, people who experience incarceration are often unable to access this curative
therapy, and are often not readily engaged in medical care upon release. This perpetuates
transmission and progression of disease in an incredibly high risk, marginalized population.
Therefore, in order to effectively eliminate HCV, it is imperative that the epidemic of HCV
in prisons is addressed, and that models of care are established for treatment of HCV in
incarcerated individuals, both during and after incarceration.
As such, the investigators propose a comprehensive model of care to engage incarcerated
individuals in treatment of HCV upon release from prison. This care is provided in
conjunction with collocated services to prevent HCV reinfection, including opioid agonist
therapy. This pilot trial will demonstrate whether a comprehensive model of care can
effectively cure HCV in recently incarcerated individuals, while simultaneously treating
opioid use disorder and preventing HCV reinfection.
Phase:
Phase 4
Details
Lead Sponsor:
University of Maryland, Baltimore
Collaborators:
Maryland Department of Public Safety and Correctional Services Merck Sharp & Dohme Corp.